A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Parallel Efficacy Laboratory Classroom Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder
Phase of Trial: Phase III
Latest Information Update: 11 Dec 2017
At a glance
- Drugs KP-415 (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- Sponsors KemPharm
- 05 Dec 2017 Status changed from not yet recruiting to recruiting.
- 08 Nov 2017 Planned initiation date changed from 1 Oct 2017 to 1 Dec 2017.
- 22 Sep 2017 Status changed from planning to not yet recruiting.